Please Wait.....
Report
Global Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 673 Pages I Data Bridge Market Research
Global Kidney Cancer Diagnostics Market is projected to register a CAGR of 6.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I , Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research),End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel, the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America), Industry Trends and Forecast to 2030.
.
Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:
- Rising healthcare expenditure for better health services
- Rising Awareness about kidney cancer
- Increase in diagnostic procedure for kidney cancer
Market Players
Some of the key market players for global kidney cancer diagnostics market are listed below:
- Ambry Genetics
- BD
- BioVendor R&D
- BluePrint Oy.
- Canon Medical Systems Corporation
- CD Genomics
- CENTOGENE N.V.
- Creative Diagnostics
- FUJIFILM Corporation
- GeneDx, LLC
- GenPath
- Grail
- Illumina, Inc.
- Invitae Corporation
- Koninklijke Philips N.V.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Qiagen
- Seimens Healthcare GmbH
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1 INTRODUCTION 85
1.1 OBJECTIVES OF THE STUDY 85
1.2 MARKET DEFINITION 85
1.3 OVERVIEW OF THE GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET 85
1.4 CURRENCY AND PRICING 87
1.5 LIMITATIONS 88
1.6 MARKETS COVERED 88
2 MARKET SEGMENTATION 92
2.1 MARKETS COVERED 92
2.2 GEOGRAPHICAL SCOPE 93
2.3 YEARS CONSIDERED FOR THE STUDY 94
2.4 DBMR TRIPOD DATA VALIDATION MODEL 95
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 98
2.6 MULTIVARIATE MODELLING 99
2.7 MARKET APPLICATION COVERAGE GRID 100
2.8 TEST TYPE LIFELINE CURVE 101
2.9 DBMR MARKET POSITION GRID 102
2.10 VENDOR SHARE ANALYSIS 103
2.11 SECONDARY SOURCES 104
2.12 ASSUMPTIONS 104
3 EXECUTIVE SUMMARY 105
4 PREMIUM INSIGHTS 108
4.1 PESTEL ANALYSIS 111
4.2 PORTER'S 5 FORCES 112
4.3 EPIDEMIOLOGY 113
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 114
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 114
5 INDUSTRY INSIGHTS 115
6 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 117
7 MARKET OVERVIEW 120
7.1 DRIVERS 122
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 122
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 124
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 125
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 125
7.2 RESTRAINTS 126
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 126
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 127
7.3 OPPORTUNITIES 127
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 127
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 128
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 128
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 129
7.4 CHALLENGES 129
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 129
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 130
8 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131
8.1 OVERVIEW 132
8.2 IMAGING 136
8.2.1 COMPUTED TOMOGRAPHY 137
8.2.2 ULTRASOUND 137
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 137
8.2.4 ANGIOGRAPHY 137
8.2.5 X-RAY 137
8.2.6 OTHERS 137
8.3 BLOOD TEST 137
8.4 BIOPSY 138
8.4.1 FINE NEEDLE ASPIRATION 139
8.4.2 NEEDLE CORE BIOPSY 139
8.5 BIOMARKER TEST 139
8.5.1 AQUAPORIN 1 (AQP1) 141
8.5.2 PERILIPIN (PLIN2) 141
8.5.3 N-METHYLTRANSFERASE (NMNT) 141
8.5.4 L-PLASTIN (LCP-1) 141
8.5.5 NM23A 141
8.6 GENETIC TEST 141
8.7 OTHERS 142
9 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 144
9.1 OVERVIEW 145
9.2 STAGE I 148
9.3 STAGE II 148
9.4 STAGE III 149
9.5 STAGE IV 150
10 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 151
10.1 OVERVIEW 152
10.2 RENAL CELL CARCINOMA 156
10.2.1 IMAGING 157
10.2.2 BLOOD TEST 157
10.2.3 BIOPSY 157
10.2.4 BIOMARKER TEST 157
10.2.5 GENETIC TEST 157
10.2.6 OTHERS 157
10.3 CLEAR CELL RENAL CELL CARCINOMA 157
10.3.1 IMAGING 159
10.3.2 BLOOD TEST 159
10.3.3 BIOPSY 159
10.3.4 BIOMARKER TEST 159
10.3.5 GENETIC TEST 159
10.3.6 OTHERS 159
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 159
10.4.1 PAPILLARY RENAL CELL CARCINOMA 160
10.4.1.1 IMAGING 161
10.4.1.2 BLOOD TEST 161
10.4.1.3 BIOPSY 161
10.4.1.4 BIOMARKER TEST 161
10.4.1.5 GENETIC TEST 161
10.4.1.6 OTHERS 161
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 161
10.4.2.1 IMAGING 162
10.4.2.2 BLOOD TEST 162
10.4.2.3 BIOPSY 162
10.4.2.4 BIOMARKER TEST 162
10.4.2.5 GENETIC TEST 162
10.4.2.6 OTHERS 162
11 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 163
11.1 OVERVIEW 164
11.2 INSTRUMENT BASED PRODUCTS 168
11.2.1 IMAGING 169
11.2.2 BIOPSY 169
11.3 PLATFORM BASED PRODUCTS 169
11.3.1 NEXT GENERATION SEQUENCING 171
11.3.2 MICROARRAYS 171
11.3.3 PCR 172
11.3.4 OTHERS 172
11.4 KITS AND REAGENTS 172
11.4.1 RENAL CANCER PANELS 174
11.4.2 RENAL CANCER ANTIBODIES 174
11.5 OTHER CONSUMABLES 174
12 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 175
12.1 OVERVIEW 176
12.2 FLUORESCENT IN SITU HYBRIDIZATION 179
12.3 NEXT GENERATION SEQUENCING 179
12.4 FLUORIMMUNOASSAY 180
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 181
12.6 IMMUNOHISTOCHEMICAL 182
12.7 OTHERS 182
13 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 184
13.1 OVERVIEW 185
13.2 SCREENING 188
13.2.1 INSTRUMENT BASED PRODUCTS 189
13.2.2 PLATFORM BASED PRODUCTS 189
13.2.3 KITS AND REAGENTS 189
13.2.4 OTHER CONSUMABLES 189
13.3 DIAGNOSTIC AND PREDICTIVE 189
13.3.1 INSTRUMENT BASED PRODUCTS 190
13.3.2 PLATFORM BASED PRODUCTS 190
13.3.3 KITS AND REAGENTS 190
13.3.4 OTHER CONSUMABLES 190
13.4 PROGNOSTIC 191
13.4.1 INSTRUMENT BASED PRODUCTS 192
13.4.2 PLATFORM BASED PRODUCTS 192
13.4.3 KITS AND REAGENTS 192
13.4.4 OTHER CONSUMABLES 192
13.5 RESEARCH 192
13.5.1 INSTRUMENT BASED PRODUCTS 193
13.5.2 PLATFORM BASED PRODUCTS 193
13.5.3 KITS AND REAGENTS 193
13.5.4 OTHER CONSUMABLES 194
14 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 195
14.1 OVERVIEW 196
14.2 HOSPITALS 199
14.3 DIAGNOSTIC CENTERS 199
14.4 CANCER RESEARCH CENTERS 200
14.5 ACADEMIC INSTITUTES 201
14.6 AMBULATORY SURGICAL CENTERS 201
14.7 OTHERS 202
15 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 203
15.1 OVERVIEW 204
15.2 DIRECT TENDER 207
15.3 RETAIL SALES 207
15.4 OTHERS 208
16 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 209
16.1 OVERVIEW 210
16.2 NORTH AMERICA 216
16.2.1 U.S. 230
16.2.2 CANADA 239
16.2.3 MEXICO 248
16.3 ASIA-PACIFIC 257
16.3.1 CHINA 270
16.3.2 JAPAN 277
16.3.3 INDIA 284
16.3.4 SOUTH KOREA 291
16.3.5 AUSTRALIA 298
16.3.6 TAIWAN 305
16.3.7 NEW ZEALAND 313
16.3.8 INDONESIA 320
16.3.9 THAILAND 327
16.3.10 PHILIPPINES 334
16.3.11 MALAYSIA 341
16.3.12 VIETNAM 348
16.3.13 SINGAPORE 355
16.3.14 REST OF ASIA PACIFIC 362
16.4 EUROPE 363
16.4.1 GERMANY 379
16.4.2 FRANCE 388
16.4.3 UNITED KINGDOM 397
16.4.4 ITALY 406
16.4.5 SPAIN 415
16.4.6 RUSSIA 424
16.4.7 NETHERLANDS 433
16.4.8 POLAND 442
16.4.9 SWITZERLAND 451
16.4.10 BELGIUM 460
16.4.11 SWEDEN 469
16.4.12 NORWAY 478
16.4.13 DENMARK 487
16.4.14 FINLAND 496
16.4.15 TURKEY 505
16.4.16 REST OF EUROPE 514
16.5 SOUTH AMERICA 515
16.5.1 BRAZIL 527
16.5.2 ARGENTINA 534
16.5.3 REST OF SOUTH AMERICA 542
16.6 MIDDLE EAST AND AFRICA 543
16.6.1 SOUTH AFRICA 556
16.6.2 SAUDI ARABIA 563
16.6.3 BAHRAIN 571
16.6.4 U.A.E. 578
16.6.5 EGYPT 586
16.6.6 ISRAEL 594
16.6.7 KUWAIT 602
16.6.8 OMAN 610
16.6.9 QATAR 618
16.6.10 REST OF MIDDLE EAST AND AFRICA 626
17 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 627
17.1 COMPANY SHARE ANALYSIS: GLOBAL 627
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 628
17.3 COMPANY SHARE ANALYSIS: EUROPE 629
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 630
18 SWOT ANALYSIS 631
19 COMPANY PROFILE 632
19.1 CANON MEDICAL SYSTEMS CORPORATION 632
19.1.1 COMPANY SNAPSHOT 632
19.1.2 REVENUE ANALYSIS 632
19.1.3 COMPANY PROFILE 633
19.1.4 PRODUCT PORTFOLIO 633
19.1.5 RECENT DEVELOPMENT 633
19.2 KONINKLIJKE PHILIPS N.V. 634
19.2.1 COMPANY SNAPSHOT 634
19.2.2 REVENUE ANALYSIS 634
19.2.3 COMPANY PROFILE 635
19.2.4 PRODUCT PORTFOLIO 635
19.2.5 RECENT DEVELOPMENTS 636
19.3 GENERAL ELECTRIC COMPANY 637
19.3.1 COMPANY SNAPSHOT 637
19.3.2 REVENUE ANALYSIS 637
19.3.3 COMPANY PROFILE 638
19.3.4 PRODUCT PORTFOLIO 638
19.3.5 RECENT DEVELOPMENTS 639
19.4 SIEMENS HEALTHCARE GMBH 640
19.4.1 COMPANY SNAPSHOT 640
19.4.2 REVENUE ANALYSIS 640
19.4.3 COMPANY PROFILE 641
19.4.4 PRODUCT PORTFOLIO 641
19.4.5 RECENT DEVELOPMENT 642
19.5 GRAIL 643
19.5.1 COMPANY SNAPSHOT 643
19.5.2 PRODUCT PORTFOLIO 643
19.5.3 RECENT DEVELOPMENTS 643
19.6 AMBRY GENETICS 645
19.6.1 COMPANY SNAPSHOT 645
19.6.2 PRODUCT PORTFOLIO 645
19.6.3 RECENT DEVELOPMENT 645
19.7 BIOVENDOR R&D 646
19.7.1 COMPANY SNAPSHOT 646
19.7.2 PRODUCT PORTFOLIO 646
19.7.3 RECENT DEVELOPMENT 646
19.8 BLUEPRINT GENETICS OY. 647
19.8.1 COMPANY SNAPSHOT 647
19.8.2 PRODUCT PORTFOLIO 647
19.8.3 RECENT DEVELOPMENT 647
19.9 CD GENOMICS 648
19.9.1 COMPANY SNAPSHOT 648
19.9.2 PRODUCT PORTFOLIO 648
19.9.3 RECENT DEVELOPMENT 648
19.10 CENTOGENE N.V. 649
19.10.1 COMPANY SNAPSHOT 649
19.10.2 REVENUE ANALYSIS 649
19.10.3 PRODUCT PORTFOLIO 650
19.10.4 RECENT DEVELOPMENT 650
19.11 CREATIVE DIAGNOSTICS 651
19.11.1 COMPANY SNAPSHOT 651
19.11.2 PRODUCT PORTFOLIO 651
19.11.3 RECENT DEVELOPMENT 651
19.12 FUJIFILM CORPORATION 652
19.12.1 COMPANY SNAPSHOT 652
19.12.2 REVENUE ANALYSIS 652
19.12.3 PRODUCT PORTFOLIO 653
19.12.4 RECENT DEVELOPMENTS 653
19.13 GENEDX, LLC 654
19.13.1 COMPANY SNAPSHOT 654
19.13.2 REVENUE ANALYSIS 654
19.13.3 PRODUCT PORTFOLIO 655
19.13.4 RECENT DEVELOPMENT 655
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY 656
19.14.1 COMPANY SNAPSHOT 656
19.14.2 PRODUCT PORTFOLIO 656
19.14.3 RECENT DEVELOPMENT 656
19.15 ILLUMINA, INC. 657
19.15.1 COMPANY SNAPSHOT 657
19.15.2 REVENUE ANALYSIS 657
19.15.3 PRODUCT PORTFOLIO 658
19.15.4 RECENT DEVELOPMENT 658
19.16 INVITAE CORPORATION 659
19.16.1 COMPANY SNAPSHOT 659
19.16.2 REVENUE ANALYSIS 659
19.16.3 PRODUCT PORTFOLIO 660
19.16.4 RECENT DEVELOPMENT 660
19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 661
19.17.1 COMPANY SNAPSHOT 661
19.17.2 REVENUE ANALYSIS 661
19.17.3 PRODUCT PORTFOLIO 662
19.17.4 RECENT DEVELOPMENTS 662
19.18 MYRIAD GENETICS, INC. 663
19.18.1 COMPANY SNAPSHOT 663
19.18.2 REVENUE ANALYSIS 663
19.18.3 PRODUCT PORTFOLIO 664
19.18.4 RECENT DEVELOPMENT 664
19.19 THERMO FISHER SCIENTIFIC INC. 665
19.19.1 COMPANY SNAPSHOT 665
19.19.2 REVENUE ANALYSIS 665
19.19.3 PRODUCT PORTFOLIO 666
19.19.4 RECENT DEVELOPMENT 666
19.20 QIAGEN 667
19.20.1 COMPANY SNAPSHOT 667
19.20.2 REVENUE ANALYSIS 667
19.20.3 PRODUCT PORTFOLIO 668
19.20.4 RECENT DEVELOPMENT 668
20 QUESTIONNAIRE 669
21 RELATED REPORTS 673
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security